Breakthrough Antibody 3E1 Provides Safe, Lasting Pain Relief
Researchers at Kindai University have developed an antibody, 3E1, that targets the cell adhesion molecule CADM1, offering long-lasting pain relief without side effects. The antibody selectively acts on sensory nerves, reducing pain perception by altering CADM1 expression on nerve fibers. Unlike previous nerve growth factor inhibitors, 3E1 does not cause severe side effects, making it a promising alternative in pain management. The study highlights the potential of 'antibody anesthetics' and suggests further development for human use.